Adaptive methods: When and how should they be used in clinical trials?

Therapie

Volumn 66, Issue 4, 2011, Pages 319-326

  Porcher, Raphaël ^a   Lecocq, Brigitte ^b   Vray, Muriel ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b NOVARTIS PHARMA K K   (Japan)

^c INSTITUT PASTEUR   (France)

Author keywords

Adaptative trial; Experimental design amendement; Interim analysis; Treatment selection

Indexed keywords

ARTICLE; BAYES THEOREM; CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; EXPLORATORY RESEARCH; HUMAN; METHODOLOGY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESEARCH SUBJECT; SAMPLE SIZE; STUDY DESIGN; SYSTEMATIC ERROR;

EID: 80052010238     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2011044     Document Type: Article

References (36)

1. Bretz F, Schmidli H, König F, et al. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biom J 2006; 48: 623-34
2. Gallo P, Chuang-Stein C, Dragalin V, et al. Adaptive designs in clinical drug development. An executive summary of the PhRMA Working Group. J Biopharm Stat 2006; 16: 275-83
3. Bretz F, Koenig F, Brannath W, et al. Adaptive designs for confirmatory clinical trials. Stat Med 2009; 28: 1181-217
4. Bretz F, Branson M, Burman CF, et al. Adaptivity in drug discovery and development. Drug Development Research 2009; 70:169-90
5. Schmidli H, Bretz F, Racine A, et al. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations. Biom J 2006; 48: 635-43
6. FDA. Critical Path Opportunities List. 2006 initiatives/criticalpath/
7. CHMP. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2009 . eu/docs/en-GB/document-library/ Scientific-guideline/ 2009/09/WC500003616.pdf
8. FDA. Guidance for Industry: adaptive design clinical trials for drugs and biologics. 2010 guidancecomplianceregulatoryinformation/guidances/ ucm201790.pdf
9. Dragalin V. Adaptive designs: terminology and classification. Drug Info J 2006; 40: 425-35
10. Brannath W, Koenig F, Bauer P. Multiplicity and flexibility in clinical trials. Pharm Stat 2007; 6: 205-16
11. CPMP. ICH E9: note for guidance on statistical priniples for clinical trials [Internet]. 1998 en-GB/document-library/Scientific-guideline/2009/09/ WC500002928.pdf
12. Bauer P, Brannath W, PoschM. Flexible two-stage designs: an overview. Meth Info Med 2001; 40: 117-21
13. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029-41
14. Brannath W, Posch M, Bauer P. Recursive combination tests. J Am Statist Assoc 2002; 97(457): 236-44
15. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995; 51: 1315-24
16. Posch M, Bauer P. Adaptive two stage designs and the conditional error function. Biom J 1999; 41: 689-96
17. Marcus R, Eric P, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63: 655-60
18. Spiegelhalter DJ, Abrams KR,Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester: Wiley, 2004
19. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46: 33-48
20. Berry DA, Mueller P, Grieve AP, et al. Adaptive Bayesian designs for doseranging drug trials. Case Studies in Bayesian Statistics 2001; 5: 99-181
21. Schmidli H, Bretz F, Racine Poon A. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Stat Med 2007; 26: 4925-38
22. Berry SM, Carlin BP, Lee JJ, et al. Bayesian adaptive methods for clinical trials. Boca Raton: CRC Press, 2010
23. Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clin Trials 2006; 3: 57-71
24. O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dosefinding studies. Br J Cancer 2006; 94: 609-13
25. Levy V, Zohar S, Bardin C, et al. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 2006; 95: 253-9
26. Huang X, Biswas S, Oki Y, et al. A parallel phase I/II clinical trial design for combination therapies. Biometrics 2007; 63: 429-36
27. Posch M, Koenig F, Branson M, et al. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med 2005; 24: 3697-714
28. Liu Q, Pledger GW. Phase 2 and 3 combination designs to accelerate drugdevelopment. J Am Statist Assoc 2005; 100(470): 493-502
29. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Resp Crit Care Med 2010; 182: 155-62
30. Chuang-Stein C, Anderson K, Gallo P, et al. Sample size re-estimation: a review and recommendations. Drug Info J 2006; 40: 475-84
31. Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90: 367-78
32. Burman CF, Sonesson C. Are flexible designs sound? Biometrics 2006; 62: 664-9
33. Bauer P, Koenig F. The reassessment of trial perspectives from interim data-a critical view. Stat Med 2006; 25: 23-36
34. Desseaux K, Porcher R. Flexible two-stage design with sample size reassessment for survival trials. Stat Med 2007; 26: 5002-13
35. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007; 6: 227-44
36. Brannath W, Zuber E, Branson M, et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Stat Med 2009; 28: 1445-63